Navigation Links
Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
Date:11/16/2007

BERKELEY HEIGHTS, N.J., Nov. 16 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that it has received a Staff Determination letter from the NASDAQ Stock Market stating that the Company's common stock is subject to delisting from The NASDAQ Global Market because the Company does not comply with the requirement to maintain a minimum $10,000,000 value in stockholders' equity, as set forth in Marketplace Rule 4450(a)(3). The Company intends to provide a plan to NASDAQ Staff to resume compliance with the Marketplace Rule on or before November 27, 2007. However, the Company cannot make any representation that NASDAQ Staff will accept this plan. A delisting decision by NASDAQ Staff may be appealed to a NASDAQ Listing Qualifications Panel.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated wi
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
8. IsoTis Receives FDA Clearance for Accell Family of Products
9. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...DO recently announced that Dr. Dominique Hebrault ...ocess Analytical Technology (PAT) in Green Chemist...9. , (PRWEB) November 20,...l Technology (PAT) in Green Chemistry and Green En...al Technology (PAT) case studies will be presented...
(Date:11/19/2009)...e-FirstCall/ -- Omeros Corporation (Nasdaq: OMER ...the third quarter ended September 30, 2009. For th...ported a net loss of $3.9 million, or $1.34 per sh... $2.54 per share, for the same period in 2008. For...pany reported a net loss of $15.5 million, or $5.2...
(Date:11/19/2009)...re-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ),...tter to its shareholders, discussing the Company,s...rmaceuticals Holdings, Inc. (CHBP), an integrated ...epublic of China. The merger gives NeoStem a contr...Co. Ltd., CHBP,s primary operating subsidiary and ...
(Date:11/19/2009)...vember 19 MONITORING FORCE GmbH,an...9 Flibanserin in the,indication treatment-relevant...e for orphan drug status designation with the Euro...kinesia is a complication of the mainstay,treatmen...some of those,affected, since it may be disabling ...
Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
...h Strategies Group, a leading provider of market i...y industries, analyzed trends shaping future sales...ategies to address these new models at the 38th An...s (SPBT) Conference, held May 11-14 in Chicago. , ... ," consultants Denise Woltemath and Manny Gaspar...
... ALL Highlighted at the 14th Congress of the Europ... Combination Data in Breast Cancer to Be Presented...O) Meeting , , BETHESDA, Md., May 20 Micromet, I... developing novel, proprietary antibodies for the ...iseases, today announced an oral(1) and a poster p...
...therlands, May 19 InfraReDx, Inc. announced today...heter that uses both light and sound to image coro... Serruys, Dr. Martin van der Ent performed the pro...onary angiography at the Thoraxcenter. , , The ... IVUS and NIRS imaging in a single study of the ar...
Other Biology Technology:Health Strategies Group Forecasts Emerging Trends in Future Sales Force Models at the SPBT 2009 Conference 2Health Strategies Group Forecasts Emerging Trends in Future Sales Force Models at the SPBT 2009 Conference 3Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 2Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 3Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 4Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 5First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter 2First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter 3
(Date:11/20/2009)...c dust: Toxins in coal-tar-based sealcoats in park...dust, according to a USGS study. PAHs or polycyc...nd in oil, coal and tar deposits, and can have tox...en found in house dust; however, the specific sour...chers found that dust from indoor areas near parki...
(Date:11/20/2009)...mass from the production of flax shives, and gener...lant related to those which engulf fields in sprin...n suggested by two studies carried out by Spanish ... Renewable and Sustainable Energy Reviews . , "T... of view, the production of bioethanol from two, a...
(Date:11/19/2009)...rally occurring brain chemical with an unwieldy na...an be abused or used as a date-rape drug. , Now...rmined new routes by which 4-HB is metabolized by ... said K. Michael Gibson, professor and chair of bi...sity and a member of the research team. "It may p...
Breaking Biology News(10 mins):From toxic dust and algae to ill winds from Africa 2From toxic dust and algae to ill winds from Africa 3From toxic dust and algae to ill winds from Africa 4From toxic dust and algae to ill winds from Africa 5Flax and yellow flowers can produce bioethanol 2Researchers begin to decipher metabolism of sexual assault drug 2New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 1New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 2New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 3New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 4New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 5New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 6New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 7New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 8New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 9New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 10Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences 5693 1Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences 5693 2M D Anderson redefines screening guidelines for breast cervical and colorectal cancers 60091 1M D Anderson redefines screening guidelines for breast cervical and colorectal cancers 60091 2M D Anderson redefines screening guidelines for breast cervical and colorectal cancers 60091 3M D Anderson redefines screening guidelines for breast cervical and colorectal cancers 60091 4
... geneticists have found links in the cell death ma...for studying and targeting a process vital to deve...seases. , The work, reported in the February 17 i...ria, the cellular power plant, in prompting worm c...ath models along the evolutionary spectrum, from s...
...mals are more dramatic than when they band togethe...xamples are the many thousands of wildebeests and ...cross the African plains. , Countless millions of...s unite with their own kind and form teeming, hung... path that,s edible. Some spectacular marching pac...
...ers at UT Southwestern Medical Center challenge on...unicate with one another. , Every time we move, f...or neurons, in our body transmit messages to one a...rs. Within neurons are tiny organelles called syna... release them when needed into the synapse, or spa...
Other Biology News:Critical role in programmed cell death identified 2Critical role in programmed cell death identified 3Experiments provide proof of how traveling in groups protects insects 2New research questions basic tenet of neuron function 2
Rabbit Anti-SMURF 2 Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Nuclear Receptor Coactivator 2 (NCOA2) Polyclonal Antibody, Agarose Conjugated from Novus Biologicals
Rabbit Anti-Mouse Zinc Finger Protein of Cerebellum 2 Polyclonal Antibody, Unconjugated from Meridian Life Science, Inc.
2,7-Dichlorofluorescein (Fluorescence Reference Standard) from AnaSpec
Biology Products: